Earnings History Data for Oncotelic Therapeutics (OTLC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Oncotelic Therapeutics

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
Release Date Time Est. Time Symbol Name Market Cap (M) Rep. EPS Est. EPS Last years EPS SeekingAlpha Headline Price Change Ext. Hours Price Ext. Hours Change 52 Week Range Volume Avg. Volume Ext. Hours Volume Top Mover
18-04-2022 PM OTLC Oncotelic Therapeutics 87.00 N/A -0.01 0.00 0.2250 -0.01 
(-2.24%)
0.0 0.0 
(0.00%)
0.08 - 0.34 136,152 0 0